Marijuana’s New Status: A Game-Changer for Businesses

Close-up of vibrant green cannabis leaves

A new policy threatens Second Amendment rights, sparking outrage among patriots.

Story Highlights

President Trump signs executive order to move marijuana to Schedule III.
No credible sources confirm fentanyl as a Weapon of Mass Destruction.
Move impacts cannabis industry significantly, opening banking opportunities.
Potential tax relief for cannabis businesses under new classification.

Trump’s Executive Order and Its Impact

On December 18, 2025, President Donald Trump signed an executive order to expedite the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act. This significant move aims to reduce regulatory burdens and enhance medical research. The executive order mandates the Attorney General to finalize this transfer promptly, a shift anticipated to relieve cannabis businesses from the burdensome Section 280E tax restrictions.

This policy change, however, does not align with claims about fentanyl being declared a Weapon of Mass Destruction. Despite some sensationalized reports, no credible sources confirm such a declaration. The rescheduling of marijuana is based on scientific evaluations and administrative processes, while WMD designations require specific legislative actions, which have not occurred for fentanyl.

Economic Implications for the Cannabis Industry

Rescheduling marijuana to Schedule III is poised to transform the cannabis industry, particularly by eliminating the prohibitive tax burdens of Section 280E. This change allows cannabis businesses to claim tax deductions, potentially boosting profits by 30-70%. Moreover, it opens doors for increased banking opportunities, as financial institutions previously hesitant due to federal laws may reconsider their stance.

While this move marks a substantial victory for the cannabis sector, it remains federally controlled, preventing full descheduling. The industry, however, views this as a “watershed” moment, anticipating significant economic growth and stability.

Contrasting Narratives and Public Perception

Despite the clear advancements in cannabis policy, some narratives have incorrectly conflated marijuana’s rescheduling with the opioid crisis, specifically fentanyl’s classification. As of now, fentanyl remains a Schedule II substance, and no legal framework supports its classification as a Weapon of Mass Destruction. This misrepresentation likely stems from ongoing discussions about opioid policy rather than factual developments.

The Trump administration’s acceleration of cannabis rescheduling continues to face scrutiny and mixed reactions. While advocates celebrate the deregulation and increased medical access, critics remain wary of the implications for federalism and state laws. Nonetheless, the executive order underscores a pivotal shift in drug policy, reflecting a broader trend towards reform.